EGFR and neoplasm: Thus, if the expression of L858R transcripts affects the sensitivity of a tumor clone for EGFR-TKI (tyrosine kinase inhibitor) therapy, as would be expected based on IHC data [15], the poorly differentiated areas would be expected to respond better than the well differentiated areas in this individual tumor.